A61K 38/178
Lectin superfamily
Official title: {Lectin superfamily, e.g. selectins}
A61K38/178 (Lectin superfamily) appears on 69 US grants and 134 published applications in this corpus.
Search patents in A61K- Granted patents
- 69
- Published applications
- 134
- Assignees
- 89
- Inventors
- 238
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 1 |
| 2002 | 2 | 3 |
| 2003 | 0 | 3 |
| 2004 | 0 | 7 |
| 2005 | 0 | 3 |
| 2006 | 0 | 3 |
| 2007 | 1 | 2 |
| 2008 | 1 | 4 |
| 2009 | 3 | 3 |
| 2010 | 0 | 5 |
| 2011 | 0 | 2 |
| 2012 | 3 | 3 |
| 2013 | 3 | 6 |
| 2014 | 2 | 6 |
| 2015 | 4 | 4 |
| 2016 | 4 | 9 |
| 2017 | 4 | 0 |
| 2018 | 2 | 8 |
| 2019 | 4 | 7 |
| 2020 | 3 | 11 |
| 2021 | 7 | 13 |
| 2022 | 8 | 6 |
| 2023 | 6 | 5 |
| 2024 | 3 | 7 |
| 2025 | 2 | 5 |
| 2026 | 3 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- FasL-engineered biomaterials with immunomodulatory function7 Jul 2026US 12,673,073 B2Georgia Tech Research Corporation
- Genetically engineered hematopoietic stem cells and uses thereof12 May 2026US 12,622,929 B2SyzygyMed Inc.
- Antiviral lectin and uses thereof17 Mar 2026US 12,576,134 B2Academia Sinica
- Genetically engineered hematopoietic stem cells and uses thereof18 Mar 2025US 12,251,403 B2Vor Biopharma Inc.
- Methods for mobilizing stem cells7 Jan 2025US 12,188,049 B2Tzu Chi University
- Method for promoting myogenesis and skeletal muscle recovery3 Sep 2026US 2026/0256946 A1University of Miami
- Novel capsid protein variant and use thereof6 Aug 2026US 2026/0226111 A1
- Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof30 Jul 2026US 2026/0217789 A1GlycoEra AG
- Chimeric chlorotoxin receptors25 Jun 2026US 2026/0176311 A1The UAB Research Foundation
- Modified mrna therapeutics11 Jun 2026US 2026/0158108 A1Shattuck Labs, Inc.
Most cited
By later US patents
- Inhibition of heparin-binding52US 5,464,815 AGenentech, Inc. · 1995
- Method of treating rhinitis or sinusitis by intranasally administering a peptidase27US 6,337,069 B12002
- Compositions comprising E-selectin antagonists and uses therefor16US 9,254,322 B2The University of Queensland · 2016
- Treatment of immunocompromised conditions16US 9,486,497 B2The University of Queensland · 2016
- Genetically engineered hematopoietic stem cells and uses thereof9US 10,925,902 B2Vor Biopharma Inc. · 2021